secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001641172-25-014296
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics appoints Jason D. Davis, CPA, as CFO; base salary $350k
----------------------------------------------------------------------

- Jason D. Davis appointed CFO effective June 9, 2025; previously CFO at Virax Biolabs, led IPO in July 2022.
- Employment agreement includes base salary of $350k, annual bonus up to 40% of base, and sign-on cash bonus of $15k.
- Received option grant of 450,000 shares under 2022 Stock Plan; vests 1/4 on first anniversary, then monthly.
- Davis has 20+ years finance experience; at HyperDynamics increased market cap from $20M to $700M and raised $200M+.
- Appointment comes as FibroBiologics advances toward Phase 1/2 clinical trial for diabetic foot ulcers in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000164117225014296/0001641172-25-014296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000164117225014296/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-014296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer